BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int 2014;113:E67-74. [PMID: 24053727 DOI: 10.1111/bju.12442] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Gilbert N, Merseburger AS, Kramer MW. [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]. Urologe A 2017;56:604-9. [PMID: 28314973 DOI: 10.1007/s00120-017-0364-x] [Reference Citation Analysis]
2 Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao C. Management of Atypical Renal Cell Carcinomas. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0501-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Bex A, Ljungberg B, van Poppel H, Powles T; European Association of Urology. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 2016;70:901-5. [PMID: 27445002 DOI: 10.1016/j.eururo.2016.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
4 Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun 2020;23:100172. [PMID: 32252014 DOI: 10.1016/j.ctarc.2020.100172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, Briganti A, Shariat SF, Schips L, Karakiewicz PI. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. European Urology Focus 2019;5:488-96. [DOI: 10.1016/j.euf.2017.11.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
6 Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol 2019;2:643-8. [PMID: 31411994 DOI: 10.1016/j.euo.2019.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
7 Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. Curr Treat Options in Oncol 2015;16. [DOI: 10.1007/s11864-015-0337-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Vaishampayan U. Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. Curr Treat Options Oncol 2018;19:5. [PMID: 29368112 DOI: 10.1007/s11864-018-0521-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
9 Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology 2019;75:111-28. [DOI: 10.1016/j.eururo.2018.09.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 20.7] [Reference Citation Analysis]
10 Rossi SH, Klatte T, Usher-Smith JA, Fife K, Welsh SJ, Dabestani S, Bex A, Nicol D, Nathan P, Stewart GD, Wilson ECF. A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. Eur Urol Focus 2021;7:407-19. [PMID: 31530498 DOI: 10.1016/j.euf.2019.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
11 Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can Urol Assoc J 2019;13:166-74. [PMID: 31199235 DOI: 10.5489/cuaj.5786] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, Shariat SF, Schips L, Karakiewicz PI. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiology 2018;54:112-8. [DOI: 10.1016/j.canep.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Poprach A, Rumanova K, Lakomý R, Chloupková R, Stanik M, Pokrivcak T, Kiss I, Slaby O, Studentova H, Melichar B, Juracek J, Fiala O, Kopecky J, Kopeckova K, Zemanova M, Buchler T. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. Urologic Oncology: Seminars and Original Investigations 2019;37:294.e1-8. [DOI: 10.1016/j.urolonc.2018.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Tilki D, Hu B, Nguyen HG, Dall’era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-salamanca JI, Master VA, Matloob R, Mckiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology 2015;193:436-42. [DOI: 10.1016/j.juro.2014.07.087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
15 Mennitto A, Verzoni E, Grassi P, Ratta R, Fucà G, Procopio G. Multimodal treatment of advanced renal cancer in 2017. Expert Review of Clinical Pharmacology 2017;10:1395-402. [DOI: 10.1080/17512433.2017.1386552] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
16 Larcher A, Wallis CJ, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? European Urology Oncology 2019;2:365-78. [DOI: 10.1016/j.euo.2019.04.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
17 Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World J Urol 2021;39:461-72. [PMID: 32253579 DOI: 10.1007/s00345-020-03187-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Soulières D, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. Eur Urol Focus 2021;7:598-607. [PMID: 32444303 DOI: 10.1016/j.euf.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Noe A, Stewart GD, Bex A. The role of cytoreductive surgery in the era of targeted agents. Curr Opin Urol 2015;25:374-80. [PMID: 26075568 DOI: 10.1097/MOU.0000000000000192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Zhou J, Wang T, Qiu T, Chen Z, Ma X, Zhang L, Zou J. Ubiquitin-specific protease-44 inhibits the proliferation and migration of cells via inhibition of JNK pathway in clear cell renal cell carcinoma. BMC Cancer 2020;20:214. [PMID: 32164618 DOI: 10.1186/s12885-020-6713-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC, Thompson RH. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. Eur Urol 2016;69:84-91. [PMID: 26044802 DOI: 10.1016/j.eururo.2015.05.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
22 Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113:12-9. [PMID: 26086878 DOI: 10.1038/bjc.2015.196] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
23 Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol 2021;160:103287. [PMID: 33753250 DOI: 10.1016/j.critrevonc.2021.103287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kaldany A, Paulucci DJ, Kannappan M, Beksac AT, Anastos H, Okhawere K, Sfakianos JP, Badani KK. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma. Urol Oncol 2019;37:727-34. [PMID: 31174958 DOI: 10.1016/j.urolonc.2019.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targ Oncol 2018;13:705-14. [DOI: 10.1007/s11523-018-0601-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
26 Tricard T, Tsoumakidou G, Lindner V, Garnon J, Albrand G, Cathelineau X, Gangi A, Lang H. Thérapies ablatives dans le cancer du rein : indications. Progrès en Urologie 2017;27:926-51. [DOI: 10.1016/j.purol.2017.07.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Massari F, Di Nunno V, Santoni M. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417–27. European Urology Oncology 2019;2:340-1. [DOI: 10.1016/j.euo.2018.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Shen H, Liu J, Liu W, Sun J, Zheng X, Teng L, Wang X, Xie L. Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor. Cancer Med 2021;10:7492-502. [PMID: 34514731 DOI: 10.1002/cam4.4270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol 2015;33:528-37. [PMID: 26546481 DOI: 10.1016/j.urolonc.2015.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
30 Alhalabi O, Karam JA, Tannir NM. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Current Opinion in Urology 2019;29:521-5. [DOI: 10.1097/mou.0000000000000661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clinical Genitourinary Cancer 2016;14:465-72. [DOI: 10.1016/j.clgc.2016.04.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
32 Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 2015;33:339.e9-15. [PMID: 26087971 DOI: 10.1016/j.urolonc.2015.05.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
33 Blute ML Jr, Drewry A, Abel EJ. Percutaneous biopsy for risk stratification of renal masses. Ther Adv Urol 2015;7:265-74. [PMID: 26425141 DOI: 10.1177/1756287215585273] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
34 Faba OR, Brookman-May SD, Linares E, Breda A, Pisano F, Subiela JD, Sanguedolce F, Brausi M, Palou J. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. World J Urol 2017;35:1807-16. [PMID: 28702843 DOI: 10.1007/s00345-017-2072-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
35 Klaassen Z, Peard L, Wilhelm S, Coulson HC, Li Q, Kavuri SK, Terris MK, Moses KA. A Heterogeneous Renal Mass and Arm Pain in a 38-Year-old African American Female. Urology 2015;85:1229-32. [PMID: 25840460 DOI: 10.1016/j.urology.2015.02.002] [Reference Citation Analysis]
36 Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG, Sanchez A, Carlo MI, Motzer RJ, Coleman JA, Russo P, Ostrovnaya I, Chen YB, Hakimi AA. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urol Oncol 2019;37:811.e9-811.e16. [PMID: 31521530 DOI: 10.1016/j.urolonc.2019.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Narayan V, Puligandla M, Haas NB, Subramanian P, DiPaola RS, Uzzo R. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial. J Urol 2019;201:62-8. [PMID: 30130544 DOI: 10.1016/j.juro.2018.08.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sankin A, Hakimi AA, Hsieh JJ, Molina AM. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front Oncol 2015;5:67. [PMID: 25905038 DOI: 10.3389/fonc.2015.00067] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
39 Biles MJ, Patel HD, Allaf ME. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. Urol Clin North Am 2020;47:359-70. [PMID: 32600537 DOI: 10.1016/j.ucl.2020.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]